Shares of medical device company DexCom (NASDAQ:DXCM) fell 2.6% in the morning session after analysts at Piper Sandler and ...

DexCom stock rose sharply Monday after the maker of glucose monitors reported better-than-expected preliminary results for ...

BofA raised the firm’s price target on DexCom (DXCM) to $90 from $80 and keeps a Buy rating on the shares post the Q3 report. DexCom did a good job instilling confidence in its 2025 revenue target ...

Fintel reports that on January 12, 2026, Barclays downgraded their outlook for DexCom (NasdaqGS:DXCM) from Equal-Weight to ...

Raymond James lowered the firm’s price target on DexCom (DXCM) to $99 from $115 and keeps a Strong Buy rating on the shares. DexCom’s Q3 results provided modest upside to consensus, but Raymond James ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

Piper Sandler analyst Matt O’Brien raised the firm’s price target on DexCom (DXCM) to $100 from $90 and keeps an Overweight rating on the shares. The firm notes the company reported full Q4 results, ...

DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, ...

Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Shares in Dexcom plunged in extended trading Thursday after the medical devices company ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. After ...